PubMed

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.PMID: 17909087 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Ahrén B, Pacini G, Foley JE, Schweizer A.

Diabetes Care. 2005 Aug;28(8):1936-40.PMID: 16043735 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.

Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.

Horm Metab Res. 2007 Nov;39(11):826-9.PMID: 17992639 [PubMed - indexed for MEDLINE]Related articles

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S.

Diabetes Obes Metab. 2008 Sep;10(10):931-8. Epub 2007 Dec 17.PMID: 18093207 [PubMed - indexed for MEDLINE]Related articles

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28.PMID: 18957505 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE.

J Clin Endocrinol Metab. 2008 Jan;93(1):103-9. Epub 2007 Oct 9.PMID: 17925336 [PubMed - indexed for MEDLINE]Related articlesFree article

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE.

Diabetes Obes Metab. 2008 Nov;10(11):1114-24. Epub 2008 Mar 18.PMID: 18355325 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE.

J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43. Epub 2009 Jan 27.PMID: 19174497 [PubMed - indexed for MEDLINE]Related articles

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. Epub 2008 Feb 18.PMID: 18284434 [PubMed - indexed for MEDLINE]Related articles

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

Flock G, Baggio LL, Longuet C, Drucker DJ.

Diabetes. 2007 Dec;56(12):3006-13. Epub 2007 Aug 23.PMID: 17717280 [PubMed - indexed for MEDLINE]Related articlesFree article

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):166-74.PMID: 17300592 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.PMID: 16816950 [PubMed - indexed for MEDLINE]Related articles

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

Ahrén B, Foley JE.

Int J Clin Pract Suppl. 2008 Mar;(159):8-14. Review.PMID: 18269436 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.

Diabetes Obes Metab. 2008 Aug;10(8):675-82. Epub 2007 Nov 22.PMID: 18248490 [PubMed - indexed for MEDLINE]Related articles

The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.

Panina G.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:32-9. Review.PMID: 17877545 [PubMed - indexed for MEDLINE]Related articles

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.

Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.

Diabetologia. 2007 Jun;50(6):1148-55. Epub 2007 Mar 27.PMID: 17387446 [PubMed - indexed for MEDLINE]Related articles